Cellin Technologies

ChromaCon AG is a private Swiss Life Science tool company, developing and commercializing proprietary chromatographic process technology.

Our vision is to transform bioprocessing to continuous and our mission is to provide best-in-class tools consisting of equipment, reagents and discovery technologies to help our customers to create, develop and manufacture next-generation chemical and biological medicines.

We facilitate the conversion from batch to more efficient continuous processes by offering equipment, processes and software designed to ease the conversion from batch to continuous chromatography.

We are unique in providing laboratory-scale FPLC and HPLC equipment for the purification of proteins and small molecules. The systems have multiple process capabilities allowing our customers to choose the best purification process for any given purification challenge:

• conventional batch and two-step connected batch for efficient high throughput batch purification
• periodic countercurrent processes (PCC) for continuous capture and polish purification
• novel processes for discovery applications facilitating the isolation of minor components from complex mixtures

Continuous manufacturing offers 30-50% reduction in CAPEX and OPEX compared to conventional batch manufacturing and is emerging to replace batch manufacturing. ChromaCon is unique in having a full range of process and process control patents and offering together with its scale-up partner a one-stop solution from laboratory to GMP process scale.

IDT Biologika is a contract development and manufacturing organization with almost 100 years of experience in development and manufacture of live viral vaccines, gene and immune therapeutics, and fill/finish of biologics for the global protection of human health. With the expertise and capacity to handle large-scale campaign production of human vaccines and biopharmaceuticals, IDT Biologika brings development, testing and regulatory excellence along with state-of-the-art manufacturing lines required to advance projects with the highest level of quality, efficiency and consistency of supply.

Recognized for its technically sophisticated contract development, manufacture and handling of biopharmaceuticals in EMA- and FDA-inspected facilities, IDT Biologika has developed into one of the world's leading pharmaceutical and biotechnological companies.
The company's headquarters are located in Dessau-Rosslau , Germany. In the United States, IDT Biologika Corp. is responsible for sales activities throughout North America.

💡 A biotechnology group based on complementary expertise with multidisciplinary know-how

Custom Products & Services delivering a range of integrated biotechnology solutions 🤝

🏢 COMPANIES:

- RD-Biotech SAS (www.rd-biotech.com):
Custom services, Biomanufacturing and purification (monoclonal antibodies, recombinant proteins, plasmids, cells), hybridoma development, expression vectors, transfection, antibody sequencing, chimerization and humanization, analytical services and FastELISA kits for Immunoglobulins quantification and cellular contaminants detection.

- SYnAbs (www.synabs.be):
Primary and Secondary Antibodies Anti-species, Isotype controls, custom services, hybridoma development – rat, guinea pig, murine, Immunoassays

- QVQ (www.qvquality.com)
VHH Phage display services and a large range of VHH products

- Smaltis (www.smaltis.fr)
CRO specialized in microbiology, an high expertise in the fileds of antibiotic resistance, microbiota and strain engineering. Custom services and a large collection of genetically modified bacterial strains.

📈 EFFECTIVE SYNERGY

As part of a team of experts to ensure:
- The development of new biological tools in immunology, molecular biology, cellular engineering
- Identification of new markers
- The development of analytical methods
- Scientific and technical support
- The quality of services and products developed and manufactured in-house

✔ MAIN SECTORS OF ACTIVITY

- Pharmaceutical
- BioTherapeutics
- Biotechnology
- In vitro diagnostics
- Animal health
- Dermo-cosmetic
- Agribusiness
- Life sciences
- Environment
- Research Institutes

Selexis SA, a JSR Life Sciences Company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative biologic medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 130 drug products in clinical development and the manufacture of eight commercial products. As part of a comprehensive drug development

As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. In June 2017, Selexis became part of the JSR Life Sciences group. JSR’s contract development and manufacturing organization (CDMO) service offering leverages the full capabilities of Selexis’ proprietary SUREtechnology Platform™ to offer an end-to-end solution to industry. More information is available at www.selexis.com.

The SUREtechnology Platform™ incorporates a number of proprietary technologies that are unique to Selexis:

ADVANCED GENE TRANSFECTION TECHNOLOGY AND PROCEDURES
- Selexis SGE® (Selexis Genetic Elements)
- SUREtech Vectors™

MEDIA AND FEED STRATEGIES

PROPRIETARY CHO-K1 CELL LINE
- Selexis SURE CHO-M Cell Line™ (CHO-K1)

GENOME AND TRANSCRIPTOME
- SURE CHO-Mplus Libraries™
- SUREscan®

Selexis is a science-driven organization, founded on the academic interests and discoveries of its core scientific team in molecular biology, cellular physiology, and genetic engineering, and is committed to the application of these insights and methods to continuous process improvement and practical problem-solving through close interaction with its industry clients and collaborators.

Global clients, representing the complete spectrum of life science enterprises—from research laboratories and biotech startups to Big Pharma—have utilized the unparalleled proprietary technology and highly specialized services of Selexis.

Anapharm Bioanalytics is a customer-focused bioanalytical CRO specialized in small and large molecule bioanalysis. Led by a team with over 30 years’ experience in method development, validation and sample analysis, we support drug development programs for the pharmaceutical, biotechnological and generic industries worldwide.

Equipped with state-of-the-art LC-MS/MS and LBA technology platforms, Anapharm Bioanalytics provides an array of services including PK studies, biomarker testing and immunogenicity assays throughout preclinical and clinical stages. Our global network of partners allows us to provide full-service outsourcing solutions to conduct preclinical, Phase I-IV clinical trials, and bioequivalence studies for international registration.

Our clients benefit from a deep scientific expertise combined with a robust quality system. All our activities are compliant with GLP and GCP, having undergone 20 regulatory inspections by the FDA, several EU Health Authorities and ANVISA (Brazil).

Whether your drug candidate is a new chemical entity, a new biologic, a generic or a biosimilar, do not hesitate to contact us at info@anapharmbioanalytics.com.